Last reviewed · How we verify
AIMS Study: African Investigation of Mirasol System for Whole Blood. Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria
The trial will evaluate the efficacy of the Mirasol Pathogen Reduction Technology for Whole Blood to prevent Malaria transmission by transfusion of whole blood.
Details
| Lead sponsor | Terumo BCTbio |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 227 |
| Start date | 2014-03 |
| Completion | 2014-12 |
Conditions
- Malaria
Interventions
- Mirasol-treated Whole Blood
- Untreated Whole Blood
Primary outcomes
- Percentage of Participants With Incidence of Transfusion-transmitted Malaria — Up to 28 (+4) days after the initial whole blood transfusion (measured within 24 hours prior to each transfusion and at 24 (± 4) hours, 2 days, 3 days, 7 (+1) days, and 28 (+4) days after the initial whole blood transfusion)
Percentage of Participants who contracted transfusion-transmitted malaria (TTM)
Countries
Ghana